News | Treatment Planning | March 10, 2021

Brainlab Acquires Mint Medical

Together the companies will increase radiological report automation through AI and Anatomical Mapping and will create unparalleled longitudinal data

Stefan Vilsmeier Brainlab announced the acquisition of Mint Medical GmbH, a Heidelberg-based company that develops image reading and reporting software for clinical routine and research

Stefan Vilsmeier, President and CEO, Brainlab

March 10, 2021 — Brainlab announced the acquisition of Mint Medical GmbH, a Heidelberg-based company that develops image reading and reporting software for clinical routine and research. The acquisition underscores the Brainlab commitment to digital health and aims to improve the structured diagnosis, analysis and treatment of cancer and other diseases to address the demands of modern medicine and personalized treatments.

Mint Medical facilitates the diagnostic process: While working through an image exam, the radiologist is supported in capturing all primary and secondary information that is relevant to the patient’s diagnosis and therapeutic decision making. The technology-enabled, context-sensitive way of radiological reporting bridges the gap between the image and the diagnostic report, yielding a structured, yet holistic view on the individual patient’s situation and clinical history.

“The transformation of our health care system is currently focused in large part on standardizing clinical data through a coding system,” commented Stefan Vilsmeier, President and CEO, Brainlab. “However, high quality and consistency of such data requires a validated, reproducible, and structured digital process, for which Mint Medical is setting the benchmark.”

Together, market leading software-based Brainlab and Mint technologies will offer existing Mint customers the ability to link data across multiple oncological subspecialties, from clinical oncology to surgical oncology and radiotherapy. Integrating patient-reported outcomes measures (PROMs) from VisionTree, a Brainlab company, will further add valuable longitudinal data to the pool available for analysis.

Mint Medical radiology users will additionally benefit from Brainlab expertise in deep integration with a broad spectrum of standards (DICOM, FHIR, HL7) and within hospital information systems (HIS). Users will benefit from further process automation by extracting pre-existing data to prefill certain fields in the structured clinical forms. Further automation will be achieved by adding Brainlab Anatomical Mapping and context-based AI algorithms to automatically extract information from diagnostic images, more efficiently linking image data with the structured templates.

“Brainlab brings to Mint a highly compatible entrepreneurial culture, enabling us to more rapidly enhance, scale, and deploy our technology,” commented Matthias Baumhauer, President of Mint Medical. “We are excited about the tremendous opportunities for both our clinical research and clinical routine users.”

The acquisition bolsters the Brainlab oncology portfolio by frontloading the treatment planning process with more detailed, structured, and clinically relevant information. During tumor board meetings, participants will gain access to standardized reports on radiological findings to support their discussion on patient-specific treatment decisions. Post-treatment, integrating data from oncology and radiology will enhance the follow-up process through a systematic response assessment. In addition to oncology, other subspecialties like spine surgery will benefit from the technology. Structured radiological reports will allow software-driven comparison and therefore independent validation through multiple experts either in the context of a clinical trial or for quality assurance.

Mint Medical clinical trial users will benefit from Brainlab technology for cloud computing, image data analysis, and patient-reported outcomes measures, putting the patient at the center. Brainlab and Mint Medical aim to jointly improve the technological infrastructure for managing clinical trials as well as large scale registries.

For more information: www.brainlab.com

Related Content

IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
News | Radiation Oncology | September 17, 2021
September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, a
Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.
With a wealth of landmark studies in Breast, Cervical, Melanoma, Prostate, Colorectal, Oesophagus, Endocrine and Lung cancer, the ESMO Congress 2021 is a clear demonstration that oncology research has once again gathered momentum after being temporarily stopped in its tracks by the outbreak of the virus

Getty Images

News | Radiation Oncology | September 13, 2021
September 13, 2021 — At the opening press conference of the ...
Comment letters on the 2022 physician fee schedule and Radiation Oncology Model urge CMS to scale back extreme cuts that jeopardize access to life-saving cancer treatments

Getty Images

News | ASTRO | September 09, 2021
September 9, 2021 — The American Society for Radiation Oncology (AS...

Image of a STING protein, courtesy of UCLA Jonsson Comprehensive Cancer Center

News | PET Imaging | September 08, 2021
September 8, 2021 — A new study from scientists at the UCLA Jonsso...
An artificial intelligence (AI) program can spot signs of lung cancer on computed tomography (CT) scans a year before they can be diagnosed with existing methods, according to research presented at the European Respiratory Society International Congress.

Diagram showing details of the lung screening experiment. Image courtesy of the European Respiratory Society/Benoit Audelan

News | Artificial Intelligence | September 08, 2021
September 8, 2021 — An artificial intell...
Cedars-Sinai Cancer researchers have discovered that intestinal microorganisms help regulate anti-tumor immune responses to radiation treatments.

Getty Images

News | Radiation Therapy | September 01, 2021
September 1, 2021 — The study, published on Aug.